
-
AbbVie NEW YORK STOCK EXCHANGE INC.:ABBV AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. The Company strives to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.
Location: 1 N Waukegan Rd, Illinois, 60064-1802, US | Website: www.abbvie.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
408.6B
Cash
5.555B
Avg Qtr Burn
N/A
Short % of Float
0.96%
Insider Ownership
0.10%
Institutional Own.
73.98%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RINVOQ (upadacitinib) Details Giant Cell Arteritis (GCA) | Approved Quarterly sales | |
TrenibotulinumtoxinE (TrenibotE) Details Moderate to Severe Glabellar Lines | BLA Acceptance for review | |
Tavapadon Details Parkinson's disease, Brain disease | Phase 3 Update | |
Tavapadon (adjunct with L-Dopa) Details Parkinson's disease, Brain disease | Phase 3 Update | |
Darigabat Details Social Anxiety Disorder, Panic Disorder | Phase 2 Update | |
Phase 2 Update | ||
Emraclidine (CVL-231) Details Brain disease, Schizophrenia | Phase 2 Update | |
Darigabat (CVL-865) Details Epilepsy | Phase 2 Update | |
NX-13 Details Ulcerative colitis | Phase 2 Update | |
CVL-354 Details Major depressive disorder | Phase 1 Update | |
Emraclidine (CVL-231) Details Brain disease, Neurodegenerative disease, Alzheimer's disease | Phase 1 Update |